Sigmoid colon cancer - Symptoms, Causes, Treatment & Prevention

```html

Overview

Sigmoid colon cancer is a type of colorectal cancer that originates in the sigmoid colon, the S‑shaped segment of the large intestine that lies just before the rectum. It is the most common location for left‑sided colon cancers, accounting for roughly 20–30% of all colorectal cancers [1]. The disease typically develops slowly, beginning as a benign adenomatous polyp that acquires genetic mutations and becomes malignant.

While colorectal cancer can affect anyone, the incidence of sigmoid colon cancer rises with age. In the United States, the median age at diagnosis is about 68 years, and over 90% of cases are diagnosed in people older than 50 [2]. Men have a slightly higher risk than women (approximately 1.3 : 1), and certain ethnic groups—particularly African‑American and Hispanic populations—experience higher rates and poorer outcomes [3]. Worldwide, colorectal cancer (which includes sigmoid colon cancer) is the third most common cancer, with an estimated 1.9 million new cases in 2020 [4].

Symptoms

Early‑stage sigmoid colon cancer often produces few or no symptoms, which is why routine screening is crucial. When symptoms do appear, they can vary widely:

• Changes in bowel habits – persistent diarrhea, constipation, or a feeling that the bowel does not empty completely.
• Blood in stool – bright red or maroon blood, or darker, tarry stools (melena) if bleeding is higher up.
• Abdominal pain or cramping – typically left‑lower‑quadrant discomfort that may be intermittent.
• Unexplained weight loss – loss of appetite and gradual weight loss without trying.
• Feeling of fullness – especially after small meals, due to a partially obstructed lumen.
• Fatigue – often a consequence of chronic blood loss leading to iron‑deficiency anemia.
• Nausea or vomiting – more common when the tumor causes a blockage.
• Altered stool caliber – thinner or pencil‑shaped stools as the tumor narrows the bowel.

Because many of these signs overlap with benign conditions such as hemorrhoids or irritable bowel syndrome, any new, persistent, or worsening symptom should be discussed with a healthcare professional.

Causes and Risk Factors

Underlying Causes

Sigmoid colon cancer arises from a multistep process of genetic and epigenetic changes that transform normal colon epithelium into malignant cells. Key pathways include:

• Chromosomal instability (CIN) – leads to mutations in tumor‑suppressor genes like APC, TP53, and KRAS.
• Microsatellite instability (MSI) – caused by defects in DNA mismatch‑repair genes (MLH1, MSH2, MSH6, PMS2), seen in hereditary non‑polyposis colorectal cancer (Lynch syndrome).
• CpG island methylator phenotype (CIMP) – hypermethylation of promoter regions silences tumor‑suppressor genes.

Risk Factors

Many factors increase the likelihood of developing sigmoid colon cancer:

• Age ≥ 50 years – risk roughly doubles each decade after 50.
• Family history – first‑degree relative with colorectal cancer increases risk 2–3‑fold; hereditary syndromes (Lynch, familial adenomatous polyposis) raise it >10‑fold.
• Personal history of polyps or inflammatory bowel disease (IBD) – especially ulcerative colitis or Crohn’s disease involving the colon.
• Dietary patterns – high intake of red or processed meat, low fiber, and low calcium/vitamin D intake.
• Obesity & sedentary lifestyle – body‑mass index (BMI) ≥ 30 is linked to a 20–30% higher risk.
• Smoking & heavy alcohol use – each confers a modest (≈10–20%) increase.
• Diabetes mellitus – especially type 2, likely mediated by insulin resistance.
• Racial/ethnic background – African‑American individuals have a 20% higher incidence and mortality.

Diagnosis

Diagnosing sigmoid colon cancer involves a stepwise approach that combines clinical evaluation, imaging, and tissue sampling.

Initial Evaluation

• Medical history & physical exam – focus on bowel habit changes, bleeding, weight loss, and family history.
• Digital rectal exam (DRE) – can detect low‑lying tumors or palpable masses.

Screening & Diagnostic Tests

• Colonoscopy – gold standard; allows direct visualization and biopsy of suspicious lesions. Polyps can be removed during the same procedure (polypectomy).
• Fecal immunochemical test (FIT) / guaiac-based fecal occult blood test (gFOBT) – non‑invasive screening tools; positive results prompt colonoscopy.
• Stool DNA test (e.g., Cologuard) – detects molecular markers; also followed by colonoscopy if positive.

Staging Work‑up

Once cancer is confirmed, staging determines the extent of disease (TNM system) and guides treatment.

• Contrast‑enhanced CT of the abdomen & pelvis – assesses local invasion, lymph node involvement, and distant metastases (liver, lungs).
• MRI pelvis – offers superior soft‑tissue resolution for evaluating the mesorectal fascia.
• Endorectal ultrasound (EUS) – helps stage early tumors (T1–T2) when surgery is contemplated.
• Positron emission tomography (PET‑CT) – useful for detecting occult metastases or recurrence.
• Blood tests – complete blood count (look for anemia), liver function tests, and carcinoembryonic antigen (CEA) level (used as a tumor marker for monitoring).

Treatment Options

Treatment is individualized based on tumor stage, location, patient health, and personal preferences. Multidisciplinary care (surgeon, medical oncologist, radiation oncologist, gastroenterologist, dietitian) is the standard.

Surgical Management

• Segmental colectomy (sigmoidectomy) – removal of the affected sigmoid segment with adequate lymphadenectomy; most common curative approach for stages I‑III.
• Laparoscopic or robotic surgery – minimally invasive techniques associated with shorter hospital stay, less pain, and comparable oncologic outcomes.
• Open surgery – reserved for large tumors, invasion into adjacent organs, or when minimally invasive access is unsafe.
• Emergency surgery – indicated for obstruction, perforation, or uncontrolled bleeding.

Adjuvant Therapy

• Chemotherapy – typically a combination of fluoropyrimidine (5‑fluorouracil or capecitabine) plus oxaliplatin (FOLFOX or CAPOX) for stage III and high‑risk stage II disease.
• Targeted biologic agents – bevacizumab (anti‑VEGF) or cetuximab/panitumumab (anti‑EGFR) may be added for metastatic disease, depending on KRAS/NRAS mutational status.
• Radiation therapy – rarely used for sigmoid colon cancer (more common for rectal cancer), but may be considered in locally advanced cases when surgery margins are uncertain.

Systemic Therapy for Metastatic Disease

When cancer has spread (stage IV), treatment focuses on prolonging survival and symptom control:

• Combination chemo‑regimens (FOLFOX, FOLFIRI) ± biologics.
• Immunotherapy (PD‑1 inhibitors) for tumors with high microsatellite instability (MSI‑H) or mismatch repair deficiency (dMMR) [5].
• Clinical trials exploring novel agents (e.g., KRAS G12C inhibitors).

Lifestyle & Supportive Care

• Nutrition – high‑fiber, low‑red‑meat diet; adequate protein to support healing.
• Physical activity – moderate exercise (150 min/week) improves fatigue and overall prognosis.
• Psychosocial support – counseling, support groups, and survivorship programs.

Living with Sigmoid Colon Cancer

Follow‑up Schedule

• First post‑operative visit 2–4 weeks after surgery.
• Subsequent visits every 3–6 months for the first 3 years (history, physical, CEA level, colonoscopy at 1 year).
• Annual colonoscopy thereafter, or sooner if symptoms recur.

Managing Common Side Effects

• Diarrhea – Hydrate, low‑FODMAP diet, antidiarrheal agents (loperamide) as needed.
• Peripheral neuropathy (from oxaliplatin) – Dose adjustments, gabapentin, or duloxetine for pain.
• Fatigue – Balanced activity, sleep hygiene, consider iron supplementation if anemic.
• Stoma care (if a colostomy was created) – Education from wound‑ostomy nurse, skin‑protective products.

Emotional Well‑being

Living with cancer can provoke anxiety, depression, or fear of recurrence. Resources include:

• Patient assistance programs (American Cancer Society, CancerCare).
• Mindfulness‑based stress reduction (MBSR) and cognitive‑behavioral therapy (CBT).
• Peer support groups—online forums or local hospital meetings.

Prevention

While you cannot change your age or genetics, many modifiable factors lower risk:

• Regular screening – Colonoscopy every 10 years starting at age 45 (or earlier with family history). FIT annually is an alternative where colonoscopy isn’t feasible.
• Dietary changes – ≥5 servings of fruits/vegetables daily, whole grains, limit processed/red meat to < 100 g/day, increase calcium (1,200 mg) and vitamin D (600–800 IU).
• Maintain healthy weight – Aim for BMI 18.5–24.9; incorporate at least 150 min of moderate aerobic activity weekly.
• Avoid tobacco – Cease smoking; nicotinic dependence programs are effective.
• Limit alcohol – ≤2 drinks per day for men, ≤1 for women.
• Manage chronic conditions – Control diabetes, treat inflammatory bowel disease aggressively.

Complications

If left untreated or when complications arise during treatment, patients may experience:

• Intestinal obstruction – Tumor growth can block the lumen, causing pain, vomiting, and distension.
• Perforation – A hole in the colon leads to peritonitis, a surgical emergency.
• Severe bleeding – Chronic occult bleeding can cause iron‑deficiency anemia; acute massive bleed may require transfusion.
• Metastatic spread – Common sites: liver, lungs, peritoneum, and occasionally bone.
• Stoma complications – Skin irritation, prolapse, or retraction.
• Long‑term bowel dysfunction – Frequency, urgency, or “low anterior resection syndrome” after sphincter‑preserving surgery.

When to Seek Emergency Care

---

References:

1. American Cancer Society. Colorectal Cancer Facts & Figures 2023.
2. National Cancer Institute. SEER Cancer Statistics Review, 1975‑2020.
3. Centers for Disease Control and Prevention. Colorectal Cancer Disparities.
4. World Health Organization. Global Cancer Observatory: Colorectal Cancer.
5. National Comprehensive Cancer Network. Guidelines for Colon Cancer, Version 2.2024.

```